E
TBIO

Ergoteles’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

Ergoteles’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,096
Closed -$63K – 1992
2022
Q3 		$63K Sell
2,096
-102
-5% -$3.59K ﹤0.01% 1425
2022
Q2 		$71K Buy
+2,198
New +$152K ﹤0.01% 1546

Other funds holding TBIO

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ergoteles's TBIO Position: Q4 2022 in Review

Ergoteles sold out of Telesis Bio, Inc. Common Stock (TBIO) in Q4 2022, closing a stake of 2,096 shares — an estimated $63K sold.

Ergoteles first reported a position in TBIO in Q2 2022 and held it in 2 quarters. The position peaked at $71K in Q2 2022. 24 funds tracked by Wall St. Rank hold TBIO as of Q4 2022.

  • Ergoteles reported no remaining Telesis Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 2,096 Telesis Bio, Inc. Common Stock shares in Q4 2022, an estimated $63K.
  • Ergoteles first reported a position in Telesis Bio, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Telesis Bio, Inc. Common Stock position peaked at $71K in Q2 2022.
  • 24 funds tracked by Wall St. Rank held Telesis Bio, Inc. Common Stock as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.